US Bancorp DE Acquires 1,658 Shares of Janux Therapeutics, Inc. $JANX

US Bancorp DE increased its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 2,402.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,727 shares of the company’s stock after purchasing an additional 1,658 shares during the period. US Bancorp DE’s holdings in Janux Therapeutics were worth $47,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. RA Capital Management L.P. lifted its stake in Janux Therapeutics by 13.1% in the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company’s stock valued at $554,977,000 after acquiring an additional 1,200,000 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Janux Therapeutics by 41.2% in the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company’s stock valued at $190,617,000 after acquiring an additional 1,038,996 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its stake in Janux Therapeutics by 46.5% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company’s stock valued at $188,246,000 after acquiring an additional 1,115,412 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Janux Therapeutics by 47.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company’s stock valued at $163,926,000 after acquiring an additional 986,750 shares in the last quarter. Finally, Woodline Partners LP raised its stake in shares of Janux Therapeutics by 15.7% during the 4th quarter. Woodline Partners LP now owns 1,852,187 shares of the company’s stock worth $99,166,000 after purchasing an additional 251,924 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $24.70 on Wednesday. The stock’s fifty day moving average price is $24.57 and its two-hundred day moving average price is $28.06. Janux Therapeutics, Inc. has a one year low of $21.97 and a one year high of $71.71. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of -13.72 and a beta of 2.86.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.07). On average, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

JANX has been the topic of a number of analyst reports. Raymond James Financial initiated coverage on Janux Therapeutics in a research note on Friday, July 11th. They set an “outperform” rating and a $65.00 price objective on the stock. Piper Sandler initiated coverage on Janux Therapeutics in a research note on Monday. They set an “overweight” rating and a $42.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $86.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.